

# Randomized controlled trial of a postbiotic's ability to affect microbiome diversity and composition

<b>Submission date</b> 09/04/2021	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 14/09/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 06/01/2026	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

The bacteria living in the gut (the gut microbiome) can be damaged by antibiotics that are prescribed to cure an infection elsewhere in the body. This can lead to a loss of the diversity of bacteria in the microbiome. To prevent this is an open challenge. The aim of this study is to find out whether a postbiotic supplement, PBPGP22, can increase bacteria diversity in patients at the end of their antibiotic course.

### Who can participate?

Otherwise healthy adults who are prescribed antibiotics for a course of 5 days or longer for non-gut related infections

### What does the study involve?

Participants are randomly allocated to take alongside their prescribed antibiotic a commercial probiotic and either a placebo control (dummy supplement) or a postbiotic. All patients are asked to take a stool sample with an easy-to-use self-collection kit on 5 days at the end of their antibiotic course.

### What are the possible benefits and risks of participating?

The supplement may prevent antibiotic-induced damage to the gut microbiome. This may prevent inflammation, diarrhea, and other antibiotic side effects and complications. All ingredients are currently sold in the US. There is a minimal risk of allergy or adverse reaction. Fermented plant materials and probiotics have the potential for some to cause bloating or gas, an upset stomach or loose stools. The supplements used in this study have not been FDA approved. The individual ingredients have not been shown to interfere with the antibiotics prescribed, but their combination has not been tested, therefore some unknowns exist. Although the researchers will do their best to protect participants study information, there is still a very small risk of loss of privacy.

### Where is the study run from?

Baymont Emergency Room (USA)

When is the study starting and how long is it expected to run for?  
January 2018 to May 2019

Who is funding the study?  
Postbiotics Plus Research LLC (USA)

Who is the main contact?  
Aubrey Levitt  
aubrey@postbioticsplus.com

## Contact information

### Type(s)

Public

### Contact name

Ms Aubrey Levitt

### Contact details

2500 Rice Blvd  
Houston  
United States of America  
77005  
+1 (0)832 238 1781  
research@postbioticsplus.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Protocol serial number

IRB#: 120180088

## Study information

### Scientific Title

Randomized controlled trial of PBP-GP-22 to affect microbiome composition

### Acronym

PBP-GP22

### Study objectives

It is hypothesized that GP-22 taken daily during a course of prescribed oral antibiotics will increase the bacterial diversity of the gut microbiome at the end of the antibiotic course.

### Ethics approval required

Old ethics approval format

**Ethics approval(s)**

Approved 17/05/2018, New England Institutional Review Board (197 First Avenue, Suite 250, Needham, MA 02494, USA; +1 (0)617 243 3924; info@neirb.com), ref: IRB#: 120180088

**Study design**

Randomized controlled single-site double-blind interventional study

**Primary study design**

Interventional

**Study type(s)**

Prevention

**Health condition(s) or problem(s) studied**

Gut microbiome diversity loss in patients who receive antibiotics

**Interventions**

Patients are asked to take one capsule per day of PBPGP22 or a placebo alongside their prescribed antibiotic for approximately 20 days (variability arises because the intervention is given alongside a prescribed antibiotic treatment which may vary in length, intervention from the first day of the antibiotic course and until 10 days after course of antibiotics is completed).

Patients are asked to take stool samples on 5 days relative to their scheduled final day of taking the antibiotic: on their final day of taking antibiotics, the following 3 days, and on day 10 after finishing the antibiotic course. The study kit thus contains five stool sample kits with instructions, 30 GP-22 capsules or 30 placebo capsules (gelatin containing microcrystalline cellulose, identical in appearance). In addition, patients also take a daily capsule of an OTC probiotic during the trial which is included in the study kit. The study kit is barcoded but otherwise unmarked. Study kits were randomized at assembly: a random number was drawn by a computer program to assign treatment (T) or control (C).

An eligible patient who is prescribed an oral antibiotic is asked to participate by the doctor on site. If a patient chooses to participate, a staff member of the clinic or a company representative chooses an unmarked box (the study kit). The staff member or the company representative will not know the treatment arm during the handover of the study kit.

Patients send their samples by post or hand over the samples in person at the study site. Samples are submitted to a research partner for DNA sequencing. The bar codes will allow the sponsor to identify the treatment arm at the end of the trial.

Statistical analyses are included in the IRB. Briefly, diversity at the end of the antibiotic course is compared between T and C at each time point and by using time series analysis methods to compare the diversity trajectory between T and C on the first three timepoints.

**Intervention Type**

Supplement

**Primary outcome(s)**

Bacterial alpha diversity measured by 16S rRNA gene sequencing of DNA in stool samples collected at three timepoints relative to the antibiotic treatment course and quantified by the inverse Simpson diversity index: on the final day of antibiotics, the first day after completing the antibiotics course, and the second day after completing the antibiotics course

### **Key secondary outcome(s)**

1. Bacterial alpha diversity measured by 16S rRNA gene sequencing of DNA in stool samples collected at three timepoints relative to the antibiotic treatment course and quantified by the Shannon diversity index: on the final day of antibiotics, the first day after completing the antibiotics course, and the second day after completing the antibiotics course
2. Bacterial alpha diversity measured by 16S rRNA gene sequencing of DNA in stool samples collected at two timepoints relative to the antibiotic treatment course and quantified by the inverse Simpson diversity index: on the third and tenth day after completing the antibiotics course
3. Blood inflammation markers measured using C-reactive protein test at the end of antibiotic treatment course

### **Completion date**

16/05/2019

## **Eligibility**

### **Key inclusion criteria**

1. Otherwise healthy adults with a body mass index (BMI) (18-28 kg/m<sup>2</sup>)
2. Patients prescribed a course of antibiotics for 5 days or longer
3. Patients have not had another course of antibiotics in the past 6 months
4. Patients are willing to cease taking any other supplements or probiotics

### **Participant type(s)**

Patient

### **Healthy volunteers allowed**

No

### **Age group**

Mixed

### **Lower age limit**

18 years

### **Upper age limit**

110 years

### **Sex**

All

### **Total final enrolment**

32

## **Key exclusion criteria**

1. History of regular and severe constipation, diarrhea, inflammatory bowel disorder or Crohn's disease
2. Usually experience severe diarrhea (e.g. for more than 3 days) following antibiotic treatment
3. Have a compromised immune system
4. Are taking any immune modulators
5. Have an autoimmune disorder
6. Are diabetic
7. Are taking blood pressure medication
8. Have allergies to the ingredients of T or C
9. Are pregnant
10. Are nursing

## **Date of first enrolment**

17/05/2018

## **Date of final enrolment**

16/06/2018

## **Locations**

### **Countries of recruitment**

United States of America

### **Study participating centre**

**Baymont Emergency Room, LLC, Patients Emergency Room**

10133 Interstate 10 East

Baytown, Texas

United States of America

77523

## **Sponsor information**

### **Organisation**

Postbiotics Plus Research LLC

## **Funder(s)**

### **Funder type**

Industry

### **Funder Name**

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from Aubrey Levitt (aubrey@postbioticsplus.com). Data to be shared: longitudinal bacterial alpha diversity measures (inverse Simpson, Shannon), raw sequencing reads (FASTQ), anonymized metadata (treatment class, i.e. treatment or placebo control), timepoint relative to antibiotic treatment course. Data are available upon publication of the trial results for 5 years by downloading from a sequencing repository such as the sequencing reads archive (SRA). Access criteria: public de-identified data. No restrictions on analyses. Consent was obtained from all participants. Data is completely de-identified such that no Personally Identifiable Information (PII) is included in any datasets.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>		28/11/2025	06/01/2026	Yes	No
<a href="#">Participant information sheet</a>			02/09/2021	No	Yes
<a href="#">Protocol file</a>	version 2		16/09/2025	No	No